¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug research reports."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
¿µ¹® drug dependence ÇÑ±Û ¾à¹°ÀÇÁ¸(¼º)
¼³¸í   
  ¾î¶² Á¾·ùÀÇ ¾à¹°À» ¹Ýº¹Çؼ­ »ç¿ëÇϴ µ¿¾È ±× ¾àÀÇ »ç¿ëÀ» ÁßÁöÇÒ ¼ö ¾ø°Ô µÇ´Â »óÅÂ. ÀÇÁ¸ÀÇ Á¤µµ°¡ ½ÉÇØÁö¸é ¾à ¾øÀ̴ »ýȰÇÒ ¼ö ¾ø´Â »óÅ¿¡ ºüÁö°í, ±× °á°ú ¹ýÀ» ¾î±â¸é¼­±îÁö ¾àÀ» ±¸ÀÔÇϰԠµÈ´Ù. ÀÌÀü¿¡´Â ¾à¹°¸¸¼ºÁßµ¶, ¾à¹°³²¿ë, ¾à¹°½À°ü¼ºÀ̶ó´Â °³³äÀ¸·Î ³ª´©¾îÁ® ÀÖ¾úÁö¸¸, WHO¿¡¼­´Â À̰͵éÀ» ¸ðµÎ Æ÷ÇÔ½ÃÄѼ­ ¾à¹°ÀÇÁ¸À̶ó ÇÏ¿´´Ù.
  
  »óÅ¿¡ ÀÇÇÑ ºÐ·ù¶ó ¾à¹°ÀÛ¿ë¿¡ ÀÇÇÑ ºÐ·ù°¡ ÀÖ´Ù. »óÅ¿¡ ÀÇÇÑ °ÍÀº 
  
  1.Á¤½ÅÀû ÀÇÁ¸: ¾à¹°ÀÇ »ç¿ëÀ» ÁßÁöÇϸ頺ҾȰ¨-¿ì¿ï°¨-ÃÊÁ¶°¨ µîÀÇ ½É¸®ÀûÀΠÁõ»óÀÌ ³ªÅ¸³ª ´Ù½Ã ¾à¹°À» Ã£°Ô µÇ´Â °æ¿ì. ¾àÀ» ²÷¾úÀ» °æ¿ì¿¡ ³ªÅ¸³ª´Â ½ÅüÁõ»óÀΠ±Ý´ÜÁõ»óÀº ³ªÅ¸³ªÁö ¾ÊÀ¸¸ç, ¾à¹°ÀÇ Áö¼ÓÀû º¹¿ë¿¡ ÀÇÇØ¼­ Á¡Â÷ ¾à¹°¿¡ ´ëÇÑ ½ÅüÀÇ ¹ÝÀÀÀÌ ÁÙ¾îµå´Â Çö»óÀΠ¾à¹°ÀÇ ³»¼ºµµ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  
  2.½ÅüÀû ÀÇÁ¸: ¾à¹° »ç¿ëÀ» ÁßÁöÇϸ頽ÅüÀûÀΠÀå¾Ö, ÁݴÜÁõ»óÀ» ÀÏÀ¸Å°°í ±× °íÅëÀ» ´Þ·¡±â À§ÇØ ¾à¹°À» Ã£°Ô µÇ´Â °æ¿ìÀÌ´Ù. ´ëºÎºÐ ³»¼ºÀÌ ³ªÅ¸³ª´Âµ¥ °³º°ÀûÀ¸·Î ³ªÅ¸³ª´Â °æ¿ìµµ ÀÖÁö¸¸ ÁַΠº´ÇàÇØ¼­ ³ªÅ¸³­´Ù.
¿µ¹® antianginal drug ÇÑ±Û Ç×Çù½ÉÁõÁ¦
¼³¸í   
  Çù½ÉÁõÀº ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°ÔÇϰųª ½ÉÀåÀÌ Ç÷·ù¿¡ ºñÇØ¼­ ¸¹Àº ÀÏÀ» Çϴ °ÍÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Ä¡·áµÉ ¼ö ÀÖ´Ù. ¨ç nitrate°èÅëÀÇ ¾à¹°: Ç÷°üÀ» À̿ϽÃ۴ ÀÛ¿ëÀ» ÇÔÀ¸·Î½á ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù. ¨è Ä®½·Åë·ÎÂ÷´ÜÁ¦(verapamil, nifedipine): ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â CaÀÌ °ü¿©ÇÑ´Ù. Áï CaÀÌ ÀÖ¾î¾ß¸¸ ±ÙÀ°ÀÇ ¼öÃàÀÌ °¡´ÉÇØÁø´Ù. ±×·¯¹Ç·Î CaÀÌ ¼¼Æ÷¼ÓÀ¸·Î µé¾î°¡´Â °ÍÀ» ¾ïÁ¦Çϴ ¾àÁ¦´Â ±ÙÀ°ÀÇ ¼öÃàÀ» ¸·´Â´Ù. ÀÌ ¾àÀº ½ÉÀåÀÇ ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ½ÉÀå ±ÙÀ°ÀÇ ¼öÃàÀ» ¾ïÁ¦Çϸ砽ÉÀåÀÌ °úµµÇϰԠÀÏÇϴ °ÍÀ» ¸·°í, ¶Ç ½ÉÀ嵿¸ÆÀÇ ¼öÃà¿¡ °ü¿©Çϴ ±ÙÀ°¿¡ ÀÛ¿ëÀ» ÇÏ¿© ½ÉÀ嵿¸ÆÀ» À̿ϽÃÄѼ­ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù.
  
  ¨é º£Å¸Â÷´ÜÁ¦(beta-blocker): ½ÅüÀÇ ¿îµ¿·®À̳ª ±âŸÀÇ ¿ä±¸¿¡ ÀÇÇØ¼­ ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇϴ ½Å°æÀº ¹Ù·Î º£Å¸-±³°¨½Å°æÀÌ´Ù. ±³°¨½Å°æ°è¶õ »ç¶÷ÀÌ À§±ÞÇÑ »óȲ¿¡¼­ ÀÛ¿ëÇϴ ÀÚÀ²½Å°æ°èÀÌ´Ù. Áï »ç¶÷ÀÌ ±äÀåÇϰųª ½Î¿ï °æ¿ì¿¡ ÀüÇüÀûÀ¸·Î ±³°¨½Å°æ°è°¡ ÀÛ¿ëÇÑ´Ù. Áï ½ÉÀåÀÌ ¶Ù°Å³ª ¼ÒÈ­°¡ ¾ÊµÇ°Å³ª µ¿°øÀÌ Ä¿Áö´Â °Í µûÀ§°¡ ¹Ù·Î ±³°¨½Å°æ°èÀÇ ¿ªÇÒÀ̶ó°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ ±³°¨½Å°æ°è¿¡¼­ ¸»ÃÊÀå±â¿¡ º¸³»´Â ½Å°æÀÌ ±³°¨½Å°æÀÌ´Ù. ±×·¯¹Ç·Î ½ÉÀå¿¡¼­ ½ÉÀåÀ» ½Åü¿¡ Çʿ信 µû¶ó¼­ ¸¹Àº ÀÏÀ» ÇϰÔÇϴ ½Å°æÀ» Â÷´ÜÇÒ °æ¿ì¿¡´Â Çù½ÉÁõÀ» Ä¡·áÇÒ ¼ö ÀÖ°Ô µÈ´Ù(½ÉÀåÀÇ »ê¼Ò³ª ±âŸ ¿µ¾çºÐÀÇ ¼ö¿ä¸¦ ÁÙÀδÙ).
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦
  • antiobestic drug
    »ì»©´Â¾à, ºñ¸¸Ä¡·áÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antipruritic drug
    °¡·Á¿ò¾à
  • antipsychotic drug
    Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­Á¦
  • antiseborrheic drug
    Áö·ç¾à
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    1. ¹æºÎÁ¦ 2. »ì±ÕÁ¦
  • antithyroid drug
    °©»ó»ù¾à, Ç×°©»ó¼±Á¦
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • psychoactive drug
    Á¤½ÅÀÛ¿ë¾à
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • drug treatment
    ¾à¹°Ä¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹ÎÁ¦
  • antihypertensive drug
    °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
  • antimalarial drug
    ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸Á¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antipruritic drug
    °¡·Á¿ò¾à
  • antipsychotic drug
    Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­Á¦
  • antiseborrheic drug
    Áö·ç¾à
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    Ç×±Õ¾à
  • antithyroid drug
    °©»ó»ù¾à, Ç×°©»ó»ù¾àÁ¦
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiallergic drug
    Ç׾˷¹¸£±â¾à.
  • antiamebic drug
    Ç׾Ƹ޹پà.
  • antianxiety drug
    Ç׺ҾȾà(ù÷ÝÕäÌå·).
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´(Ä¡·á)¾à.
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î(¼º)¾à.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦, Ç×¹«½ºÄ«¸°(¼º)¾à
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸¾à (ù÷ÝþØ»å·).
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ¾à.
  • antipruritic drug
    Ç×¼Ò¾ç¾à£¬Áø¾ç¾à(òååÊå·), °¡·Á¿òÁ¦Áö¾à.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiamebic drug
    Ç׾Ƹ޹پà.
  • antianxiety drug
    Ç׺ҾȾà(ù÷ÝÕäÌå·).
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´(Ä¡·á)¾à.
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î(¼º)¾à.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦, Ç×¹«½ºÄ«¸°(¼º)¾à
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸¾à (ù÷ÝþØ»å·).
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ¾à.
  • antipruritic drug
    Ç×¼Ò¾ç¾à£¬Áø¾ç¾à(òååÊå·), °¡·Á¿òÁ¦Áö¾à.
  • antipsychotic drug
    Ç×Á¤½Åº´¾à(ù÷ïñãêÜ»å·).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DUR drug use review; drug utilization review
IVDA/IVDU intravenous drug abuse/ abuser; intravenous drug use/user
Rx drug; medication; pharmacy; prescribe, prescription, prescription drug; take [Lat. recipe]; therapy;...
CDER Center for Drug Evaluation and Research; chronic granulomatous disease
ERF Education and Research Foundation; external rotation in flexion; Eye Research Foundation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BMRR Brookhaven Medical Research Reactor
CBER Center for Biologics Evaluation and Research
CPCRA Community Programs for Clinical Research in AIDS
EORTC European Organisation for Research and Treatment of Cancer
EORTC European Organisation for Research on Treatment of Cancer
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
    Ç÷¾×ÀÇ ÀÀ°í¸¦ ¸·´Â ¾àÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´ Ä¡·á ¾à
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦
  • antifungal drug
    Ç×Áø±ÕÁ¦
    Áø±ÕÀÇ ¹ø½Ä°ú ¹ßÀ°À» ¾ïÁ¦ ¶Ç´Â ÀúÁöÇÏ´Â ¹°Áú, ÀÎÀÚ.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î ¾à
    È÷½ºÅ¸¹Î ÀÛ¿ë¿¡ ±æÇ×ÇÏ´Â ¾à¹°.
  • antiinflammatory drug
    ¼Ò¿°Á¦
  • antimalarial drug
    Ç׸»¶ó¸®¾ÆÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ ¾à
  • antipsychotic drug
    Ç×Á¤½Åº´ ¾à, ÇâÁ¤½Åº´ ¾à¹°
  • antiseborrheic drug
    Ç×Áö·ç ¾à
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇìŸ ¾à
  • antithyroid drug
    Ç×°©»ó¼± ¾à
  • bioreductive drug
    »ýü ȯ¿ø¼º ¾àÁ¦
  • bullous drug-induced exanthema
    ¾à¹°¿¡ ÀÇÇÑ ¼öÆ÷¼º ¹ßÁø
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
nursing administration research research concerned with establishing costs of nursing care, examining the relationships between nursing services and quality patient care, and viewing problems of nursing service delivery within the broader context of policy analysis and delivery of health services
(12 Dec 1998)
nursing education research Investigations into the problems of integrating research findings into nursing curricula, developing problem solving skills, finding approaches to clinical teaching, determining the level of practice by graduates from different basic preparations, etc.
(12 Dec 1998)
nursing evaluation research Research carried out by nurses that uses interviews, data collection, observation, surveys, etc., to evaluate nursing, health, clinical, and nursing education programs and curricula, and which also demonstrates the value of such evaluation.
(12 Dec 1998)
nursing methodology research Research carried out by nurses concerning techniques and methods to implement projects and to document information, including methods of interviewing patients, collecting data, and forming inferences. The concept includes exploration of methodological issues such as human subjectivity and human experience.
(12 Dec 1998)
nursing research Research carried out by nurses, generally in clinical settings, in the areas of clinical practice, evaluation, nursing education, nursing administration, and methodology.
(12 Dec 1998)
dental research The study of laws, theories, and hypotheses through a systematic examination of pertinent facts and their interpretation in the field of dentistry.
(12 Dec 1998)
operations research A group of techniques developed to apply scientific methods and tools to solve the problems of decision making in complex organizations and systems. Operations research searches for optimal solutions in situations of conflicting goals and makes use of mathematical models from which solutions for actual problems may be derived.
(12 Dec 1998)
epidemiologic research design The form and structure of analytic studies in epidemiologic and clinical research.
(12 Dec 1998)
united states agency for health care policy and research An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research.
(12 Dec 1998)
united states office of research integrity An office of the united states public health service organised in june 1992 to promote research integrity and investigate misconduct in research supported by the public health service. It consolidates the office of scientific integrity of the national institutes of health and the office of scientific integrity review in the office of the assistant secretary for health. The ori is in the office of the assistant secretary for health and its director reports directly to the assistant secretary for health, department of health and human services. (ri newsletter, 1993 jan; 1(1):1)
(12 Dec 1998)
abnormalities, drug-induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
(12 Dec 1998)
activity, drug A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa).
(12 Dec 1998)
addictive drug Any drug that creates a certain degree of euphoria and has a strong potential for addiction.
(05 Mar 2000)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
akathisia, drug-induced Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation).
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • market research
    ½ÃÀå Á¶»ç (¾î¶² »óǰÀÇ ¼ö¿ä¸¦ À§ÇÑ »çÀü Á¶»ç)
  • marketing research
    ½ÃÀå Á¶»ç;½ÃÀå ºÐ¼®
  • miracle drug
    Ưȿ¾à;¿µ¾à
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ÀǾàǰ
  • mood drug
    ±âºÐ ¾à(ÈïºÐÁ¦,ÁøÁ¤Á¦ µî)
  • motivational research
    µ¿±â Á¶»ç
  • operations research
    ±â¾÷ °æ¿µ»óÀÇ °úÇÐÀû Á¶»ç ¿¬±¸;ÀÛÀü ¿¬±¸
  • prescription drug
    ÀÇ»çÀÇ Ã³¹æÀüÀÌ ÇÊ¿äÇÑ ¾à
  • research
    (Çмú)¿¬±¸;°úÇÐÀû ޱ¸;ÇмúÁ¶»ç;(½ÅÁßÇÑ)¼ö»ö;ޱ¸;Á¶»ç;¿¬±¸ ´É·Â;¿¬±¸½É;¿¬±¸ÇÏ´Ù;Á¶»çÇÏ´Ù;~able
  • research and development
    ¿¬±¸¿Í °³¹ß
  • research laboratory(institute)
    ¿¬±¸¼Ò
  • research library
    ¿¬±¸ µµ¼­°ü ´Â
  • research paper
    ¿¬±¸ ³í¹®;(ÇлýÀÇ)Çб⸻ ¸®Æ÷Æ®
  • research professor
    ¿¬±¸ ±³¼ö(´ëÇÐ µî¿¡¼­ ÀÚÀ¯·ÎÀÌ ¿¬±¸¿¡ ¸ôµÎÇÒ ¼ö ÀÖ´Â ±³¼ö)
  • research reactor
    ¿¬±¸¿ë ¿øÀÚ·Î
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á